HF
BBLG

HRT Financial’s Bone Biologics BBLG Stock Holding History

HRT Financial’s Portfolio BBLG Stock Details BBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,443
Closed -$13K – 2527
2024
Q4 		$13K Sell
2,443
-1,270
-34% -$10.4K ﹤0.01% 2254
2024
Q3 		$47K Buy
3,713
+793
+27% +$7.51K ﹤0.01% 2114
2024
Q2 		$21K Buy
+2,920
New +$28.8K ﹤0.01% 1927
2023
Q1 		– Sell
-12
Closed -$3K – 2494
2022
Q4 		$3K Buy
+12
New +$6.76K ﹤0.01% 2303

Other funds holding BBLG

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

HRT Financial's BBLG Position: Q1 2025 in Review

HRT Financial sold out of Bone Biologics (BBLG) in Q1 2025, closing a stake of 2,443 shares — an estimated $13K sold.

HRT Financial first reported a position in BBLG in Q4 2022 and held it in 4 quarters. The position peaked at $47K in Q3 2024. 3 funds tracked by Wall St. Rank hold BBLG as of Q1 2025.

  • HRT Financial reported no remaining Bone Biologics position as of Q1 2025 after selling out during the quarter.
  • HRT Financial sold 2,443 Bone Biologics shares in Q1 2025, an estimated $13K.
  • HRT Financial first reported a position in Bone Biologics in Q4 2022 and held it in 4 quarters.
  • HRT Financial's Bone Biologics position peaked at $47K in Q3 2024.
  • 3 funds tracked by Wall St. Rank held Bone Biologics as of Q1 2025.

Based on HRT Financial's 13F filing for Q1 2025, filed 15 May 2025.